SCHEMBL3426237

SCHEMBL3426237

COc1nnc(-c2cn[nH]c2)cc1-c1cc2ccccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.48
KDM4E B2RXH2 4/20 0.48
MAPT P10636 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
NPC1 O15118 3/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
CYP19A1 P11511 1/20 0.42
AURKA O14965 4/20 0.42
CCNA2 P20248 3/20 0.42
CDK2 P24941 3/20 0.42
TTK P33981 3/20 0.42
FYN P06241 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1751045 0.80 KDM4E (0.47) RAB9AKDM4EMAPTMEN1KMT2A
Trifluoroacetic Acid SCHEMBL1749441 0.75 SLC22A12 (0.48) RAB9AKDM4EMAPTMEN1KMT2A
SCHEMBL3423829 0.75 CHEK1 (0.52) RAB9AKDM4EMAPTMEN1KMT2A
SCHEMBL15886938 0.72 KDM4E (0.55) RAB9AKDM4EMAPTMEN1KMT2A
SCHEMBL537355 0.71 RAB9A (0.61) RAB9AKDM4EMAPTMEN1KMT2A
SCHEMBL18446214 0.70 ITK (0.63) CCNA2CDK2CHEK1KDRITK
SCHEMBL18444005 0.70 PIM1 (0.70) ITKPIM1
SCHEMBL1751049 0.70 GSK3B (0.36) RAB9AKDM4EMAPTMEN1KMT2A
SCHEMBL18400769 0.69 KDM4E (0.51) RAB9AKDM4EMAPTMEN1KMT2A
SCHEMBL14771376 0.69 KDM4E (0.51) RAB9AKDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753743-B1 PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS DEUTSCHLAND (DE) 2015-03-04 EP disclosed
US-7709466-B2 Pyridazinone derivatives, methods for their production and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-20070088041-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088041-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS GSK3B, GSK3A, PDXK RAB9A 3790/4885KDM4E 1525/4885MAPT 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.